BIOGENA GROUP invests in Combyn Health Care

Salzburg/Graz, 19th of August 2026. The BIOGENA GROUP has taken a stake in the Austrian medtech company Combyn Health Care as part of a successfully concluded funding round. In addition to capital, the BIOGENA GROUP brings to the partnership, in particular, entrepreneurial experience, a broad medical network and strategic expertise in the fields of prevention, diagnostics and longevity.

At the centre of this collaboration is the BioCore Loop, developed by Combyn. The system combines several scientifically validated diagnostic measurement methods in a single device and, according to the company, enables fully automated health monitoring in less than five minutes. The measurement can be carried out independently and without the immediate assistance of healthcare professionals.

Among other things, the BioCore Loop records health parameters relating to the heart and circulation, the autonomic nervous system, vascular stiffness, fluid balance, muscle mass and body fat. The results are presented clearly and can assist healthcare professionals in assessing selected health risks. Furthermore, the system aids in the assessment of health risks such as osteoporosis, diabetes, sarcopenia and heart failure

BioCore Loop was developed in Austria and, according to the company, the technology has already been validated in more than 6,000 patients. The system is currently in use in specialist hospitals in Austria, as well as in research institutions in the USA and Finland, amongst other places.

“The future of medicine does not begin only when a person is ill. It begins with the early detection of changes in health and risks, and taking the appropriate action as a result,” says Dr Albert Schmidbauer, founder and CEO of the BIOGENA GROUP. “Combyn has developed a technology that makes complex health data available within a few minutes and usable for further analysis. It is this combination of science, prevention, efficiency and ease of use that has won us over.”

For BIOGENA, this investment marks a further step in its evolution from a micronutrient company into a comprehensive health ecosystem. In addition to premium micronutrients, this ecosystem also encompasses diagnostics, biohacking, longevity applications, health knowledge and personalised prevention concepts.

“We are not merely providing capital. We want to support Combyn in its further development and market expansion with our experience, our network of more than 30,000 doctors and therapists, and our access to health-conscious customers,” says Schmidbauer. “Our shared goal is to make well-founded health analyses and personalised prevention simpler, faster and accessible to significantly more people.”

With the completion of this funding round, Combyn is laying the foundations for the next phase of its corporate development. The focus is on further developing the technology, scaling up sales and integrating the BioCore Loop more closely into medical and preventive care models.

“With Albert Schmidbauer and the BIOGENA GROUP, we are gaining partners who have known the healthcare market for many years and share our vision of modern, accessible preventive medicine,” says Dr Christoph Grimmer, CEO of Combyn Health Care. “In addition to extensive entrepreneurial experience, BIOGENA brings an exceptionally strong network in the medical sector. This combination opens up valuable opportunities for us to bring our technology into widespread use more quickly.”

Professor Falko Skrabal, founder and medical adviser at Combyn Health Care, adds: “Modern medicine has access to ever-increasing amounts of data and diagnostic options. The key is to bring this information together in such a way that it can be used easily, quickly and effectively in everyday life. That is precisely why we developed the BioCore Loop.”